Her2 Inhibitors Market: Current Analysis and Forecast (2023-2030)

Her2 Inhibitors Market: Current Analysis and Forecast (2023-2030)

Her2 inhibitors are a type of cancer treatment that target the HER2 receptor, which is found on the surface of some cancer cells. These inhibitors work by blocking the HER2 receptor and preventing it from sending signals that promote the growth and spread of cancer cells. The HER2 inhibitors market is a rapidly growing segment of the cancer treatment industry, with a number of new drugs and treatments being developed and approved in recent years. These inhibitors are used to treat a variety of types of cancer, including breast, ovarian, and gastric cancer.

The Her2 Inhibitors Market is expected to grow at a strong CAGR of 7.2% during the forecast period owing to the rising prevalence of breast cancer. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer were diagnosed in women in 2021, along with 49,290 new cases of non-invasive breast cancer. Breast cancer is the most common cancer among women in the UK, with around 55,000 new cases diagnosed each year. The incidence of breast cancer in the UK has increased by around 3% over the last decade.

• Based on the drug type, the market is bifurcated into non-biologics, and biologics & biosimilars. The biologics & biosimilars held a dominant share of the market in 2022. In recent years, the demand for biologics has grown tremendously owing to their targeted nature in the management of cancer. Several pharmaceutical giants have developed biological drugs, including monoclonal antibodies, antibody-drug conjugates, and others targeting the Her-2 receptor. For instance, in August 2022, US FDA granted approval to Enhertu for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2.
• By treatment, the market is bifurcated into monotherapy and combination therapy. The combination therapy is anticipated to grow with a significant CAGR during the forecast period. The combination of anti-cancer drugs is more effective than using them individually because it targets multiple key pathways in a way that is either highly effective or adds to the overall impact. A large number of ongoing clinical trials are evaluating the role of Her-2 targeted therapy in combination with other cancer-targeting regimens, thus having a positive impact on market growth. For instance, in January 2022, Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd have announced that the New Drug Application (NDA) for the pivotal clinical trial (KN026-CSP-001) of the HER2-targeted bispecific antibody KN026 in combination with chemotherapy has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).
• Based on of application, the market is categorized into stomach cancer, breast cancer, lung cancer, and others. The breast cancer held a dominant share of the market in 2022. Currently, a large number of Her2 inhibitors have been approved for the management of breast cancer, including Herceptin, Enhertu, Tuksya, and others which is driving the growth of the segment. Moreover, the encouraging response of Her-2 inhibitors in the management of breast cancer has also propelled further research and development in this segment. For instance, in January 2021, Ambrx has announced that the US FDA has granted Fast Track Designation to ARX788 as a treatment option for advanced or metastatic HER2-positive breast cancer.
• Based on end user, the market is segmented into hospitals, clinics, and homecare. The hospitals held a dominant share of the market in 2022 owing to the rising prevalence of chronic diseases and increasing hospitalizations. The driving factors for the hospitals are numerous and include the prevalence of the disease, the advancement of treatments and technology, the quality of care provided, the availability of specialized physicians and skilled nursing staff, and the financial incentives offered by health insurance companies.
• For a better understanding of the market adoption of the dental clensing tablet industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held the dominant share of the market and is expected to do so even in the forecast period. The healthcare facilities in North America are of the highest standards and are accessible to the large population because of favorable policies making healthcare affordable to many if not all. Moreover, the increasing incidence of breast cancer cases among the population, the aging population, technological advancements, and increasing healthcare spending in several developed nations of North America region are the major factors driving the growth of the market.
• Some of the major players operating in the market include F. Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca; MacroGenics, Inc.; Puma Biotechnology, Inc.; Amgen Inc.; Biocon; Seagen Inc.; Viatris Inc.; and GSK plc.

The Her2 inhibitors market was valued at USD 13,558.82 Million and is expected to grow at a strong CAGR of around 7.2% during the forecast period (2023-2030). The market is growing with increasing government funding. Deteriorating health coupled with the rising cost of medical treatments is one of the major reasons for concern across the globe which is leading to an increase in demand for effective cancer therapeutics. Owing to this and increasing research focus on cancer treatments among researchers, many governments across the globe are taking various initiatives and have expedited their product approval process. In addition to this, many government and private organizations globally are providing funding opportunities to different cancer institutes and centers for the advancement of research across the cancer control spectrum in prevention, screening, diagnosis, treatment, rehabilitation, survivorship, and palliative care. For instance, The Canadian Cancer Society is presently providing funding and support to three center-based research initiatives that include, the Canadian Centre for Applied Research in Cancer Control (ARCC), the Canadian Cancer Trials Group (CCTG), and Propel Centre for Population Health Impact

Some of the major players operating in the F. Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca; MacroGenics, Inc.; Puma Biotechnology, Inc.; Amgen Inc.; Biocon; Seagen Inc.; Viatris Inc.; and GSK plc. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.
 
Insights Presented in the Report

“Amongst drug type, the non-biologics segment to grow with high CAGR during the forecast period”

Based on the drug type, the market is bifurcated into non-biologics, and biologics & biosimilars. The non-biologics is anticipated to grow with significant CAGR during the forecast period. Non-biologics, particularly small molecule kinase inhibitors targeting Her2 are widely available in the market. The advent of small molecule drugs for cancer therapy has been a game-changer, revolutionizing the entire cancer treatment landscape. In fact, it can be argued that the development of small molecule drugs is a greater accomplishment than any other major breakthrough in cancer therapeutics, including radiation therapy and immune cells.

“Amongst treatment, the monotherapy category held a significant share of the market in 2022”

By treatment, the market is bifurcated into monotherapy and combination therapy. The monotherapy held a dominant share of the market in 2022. Monotherapy drugs have the potential to improve patient outcomes, as they target specific molecular pathways that are critical to cancer growth and survival. Moreover, these drugs may be less expensive than combination therapies, as they require fewer drugs and less complex treatment regimens. Several monotherapeutic Her-2 regimens have received approval, thus driving the growth of the market. For instance, in August 2022, Enhertu (trastuzumab deruxtecan), a breast cancer treatment developed by AstraZeneca and Daiichi Sankyo, has been approved by the US Food and Drug Administration (FDA) for use in adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence within six months of completing adjuvant chemotherapy.

“Amongst application, the stomach cancer category to grow with high CAGR during the forecast period”

Based on application, the market is categorized into stomach cancer, breast cancer, lung cancer, and others. The stomach cancer is anticipated to grow with significant CAGR during the forecast period. Most stomach cancers are a type called adenocarcinoma, which makes up almost 90% of cases. HER2 overexpression or amplification is present in about 20% of gastric cancers. Several key pharmaceutical companies are actively working in the HER2-positive gastric cancer market, including AstraZeneca, Bayer, Bristol-Myers Squibb, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Jiangsu HengRui Medicine, Seagen, MacroGenics/Zai Lab, Merck Sharp & Dohme Corp., Eisai Inc, Merus N.V., OncXerna Therapeutics, Inc, Eli Lilly, and Company, and others. For instance, in December 2022, AstraZeneca and Daiichi Sankyo's drug Enhertu (trastuzumab deruxtecan) got approved in the European Union (EU) as a treatment option for adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.

“Asia Pacific to grow with high CAGR during the forecast period”

The Asia Pacific is anticipated to grow rapidly in the upcoming years owing to the surge in the prevalence of breast cancer and the encouraging response of Her2 inhibitors in its management. ccording to WHO, approximately 92,000 cases of breast cancer were diagnosed in Japan in 2020, with approximately 17,000 deaths. Furthermore, the domestic companies are actively investing in the development of Her2 inhibitors, thus driving the growth of the market. For instance, in January 2023, Japan’s Ministry of Health, Labour, and Welfare (MHLW) granted approval to Enhertu for the treatment of adult patients with HER2 low (IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy. Thus, these factors are driving the growth of Her2 inhibitors market in Japan.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.